Krisztian Homicsko
Overview
Explore the profile of Krisztian Homicsko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
4177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun M, Garnier L, Chevalier R, Roumain M, Wang C, Angelillo J, et al.
Nat Commun
. 2025 Jan;
16(1):1217.
PMID: 39890772
In melanoma, lymphangiogenesis correlates with metastasis and poor prognosis and promotes immunosuppression. However, it also potentiates immunotherapy by supporting immune cell trafficking. We show in a lymphangiogenic murine melanoma that...
2.
Anstett V, Heinzelmann E, Piraino F, Roch A, Chrisnandy A, Norkin M, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858076
: Developing ex vivo models that replicate immune-tumor interactions with high fidelity is essential for advancing immunotherapy research, as traditional two-dimensional in vitro systems often lack the complexity required to...
3.
Chiffelle J, Barras D, Petremand R, Orcurto A, Bobisse S, Arnaud M, et al.
Immunity
. 2024 Sep;
57(10):2466-2482.e12.
PMID: 39276771
Adoptive cell therapy (ACT) using in vitro expanded tumor-infiltrating lymphocytes (TILs) has inconsistent clinical responses. To better understand determinants of therapeutic success, we tracked TIL clonotypes from baseline tumors to...
4.
Watson S, Zomer A, Fournier N, Lourenco J, Quadroni M, Chryplewicz A, et al.
Cancer Cell
. 2024 Sep;
42(9):1507-1527.e11.
PMID: 39255775
Glioblastoma recurrence is currently inevitable despite extensive standard-of-care treatment. In preclinical studies, an alternative strategy of targeting tumor-associated macrophages and microglia through CSF-1R inhibition was previously found to regress established...
5.
Dutta D, Lorenzo-Martin L, Rivest F, Broguiere N, Tillard L, Ragusa S, et al.
NPJ Precis Oncol
. 2024 Aug;
8(1):179.
PMID: 39143103
Immunotherapy has emerged as a new standard of care for certain cancer patients with specific cellular and molecular makeups. However, there is still an unmet need for ex vivo models...
6.
Lorenzo-Martin L, Broguiere N, Langer J, Tillard L, Nikolaev M, Coukos G, et al.
Nat Biotechnol
. 2024 Jul;
PMID: 38956326
Existing organoid models fall short of fully capturing the complexity of cancer because they lack sufficient multicellular diversity, tissue-level organization, biological durability and experimental flexibility. Thus, many multifactorial cancer processes,...
7.
Liu Y, Ansaryan S, Tan J, Broguiere N, Lorenzo-Martin L, Homicsko K, et al.
Adv Sci (Weinh)
. 2024 Jun;
11(34):e2401539.
PMID: 38924371
Organoid tumor models have emerged as a powerful tool in the fields of biology and medicine as such 3D structures grown from tumor cells recapitulate better tumor characteristics, making these...
8.
Konig D, Sandholzer M, Uzun S, Zingg A, Ritschard R, Thut H, et al.
Cancer Immunol Res
. 2024 Apr;
12(7):814-821.
PMID: 38631025
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is effective in patients with melanoma, although long-term responses seem restricted in patients who have complete remissions. Many patients develop secondary resistance...
9.
Barras D, Ghisoni E, Chiffelle J, Orcurto A, Dagher J, Fahr N, et al.
Sci Immunol
. 2024 Feb;
9(92):eadg7995.
PMID: 38306416
Adoptive cell therapy (ACT) using ex vivo-expanded tumor-infiltrating lymphocytes (TILs) can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a fraction of patients. Using longitudinal samples...
10.
Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, et al.
J Immunother Cancer
. 2023 Oct;
11(10).
PMID: 37880184
Background: Few tissue biomarkers exist to date that could enrich patient with cancer populations to benefit from immune checkpoint blockade by programmed cell death protein 1/ligand-1 (PD-/L-1) inhibitors. PD-L1 expression...